TrumpRx Officially Launches, Introduces Drug Prices

President Donald J. Trump announced a shift in the pharmaceutical market with the introduction of TrumpRx as well as the implementation of Most-Favored-Nation (MFN) pricing. The central objective of this initiative is to eliminate the price disparity that impacted Americans, who saw payments up to 1000% more for the same medications manufactured in the same factories as those sold abroad.^1,2

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump said in the fact sheet.¹ “We would spend tremendous amounts of money in order to provide inexpensive drugs to another country, and when I say the price is different, you can see some examples where the price is beyond anything—4 times, 5 times different.”

By leveraging the full weight of the federal government, the administration secured agreements with major manufacturers like Eli Lilly and Novo Nordisk to ensure that domestic drug prices align with the lowest prices offered in other developed nations. This price reset is intended to end what the administration describes as "global freeloading," where American taxpayers subsidize global pharmaceutical profits and foreign health care systems while facing skyrocketing costs at home.^1,2

For pharmacists and health care providers, the most immediate impact of TrumpRx is the dramatic reduction in the list prices of high-expenditure medications, particularly those treating diabetes, heart disease, and obesity. The prices for popular glucagon-like peptide-1 medications such as semaglutide (Ozempic, Wegovy) are set to fall from over $1000 per month to as low as $199 when purchased through the TrumpRx platform. It is important to note that the price depends on dosing strength, with the lowest, 0.25/0.5, being $199 and the highest, 2/0.5, being $499. The $199 price will also be available for the first 2 months before increasing to $349.^1,2

Additionally, Eli Lilly’s tirzepatide (Zepbound), which currently carries a monthly price tag of over $1080, will be available for approximately $299 through the new system. These pricing adjustments extend to other essential treatments as well, including a $35 monthly cap on Novo Nordisk insulin products and significant discounts on migraine treatments like galcanezumab-gnlm (Emgality).^1,2

According to the website, one of the other big categories of medications includes fertility drugs. Follitropin alfa (Gonal-F), a prescription to stimulate hormones used in the treatment of infertility, is available for $168 instead of $966, and cetrorelix acetate (Cetrotide), used in IVF to prevent premature ovulation, is discounted from $316 to $22.²

The initiative also aims to broaden patient access through Medicare and Medicaid, which will now be able to cover obesity medications at a significantly lower cost to taxpayers. Medicare beneficiaries, specifically, will see their out-of-pocket costs for drugs like semaglutide and tirzepatide capped at a copay of $50 per month.¹

Beyond immediate cost savings, the administration is focusing on "Making America Healthy Again" by addressing the root causes of chronic disease, noting that obesity affects 40% of American adults and is a primary driver of type 2 diabetes and heart disease. This comprehensive approach includes realigning incentives and fostering private-sector collaboration to improve long-term public health gains.¹

To secure these benefits and mitigate supply chain vulnerabilities, the administration secured multibillion-dollar investment commitments from pharmaceutical leaders. Eli Lilly announced at least $27 billion in new US manufacturing investments, and Novo Nordisk committed an additional $10 billion to strengthen its domestic footprint, which includes plans to produce future oral medications end-to-end within the United States. This focus on domestic production is a key component of the strategy to ensure that American patients come first in the pharmaceutical supply chain.¹

REFERENCES

1. Fact sheet: President Donald J. Trump announces major developments in bringing Most-Favored-Nation pricing to American patients. The White House. November 6, 2025. Accessed February 6, 2026. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/

2. TrumpRx. Accessed February 6, 2026. https://trumprx.gov/